Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Current price $2.24
Latest analyst grade actions
1255 daily bars · split adjusted
Daily · Wilder smoothing
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 25.84 | Oscillator | Buy |
| Stochastic %K (14, 3, 3) | 1.43 | Oscillator | Buy |
| Williams %R (14) | -100.00 | Oscillator | Buy |
| MACD (12, 26, 9) | -0.31 (Hist -0.08) | Oscillator | Strong Sell |
| Average Directional Index (14) | 30.45 (+DI 10.2 / -DI 30.4) | Trend | Strong Sell |
| EMA 20 | 2.81 | MA | Strong Sell |
| SMA 20 | 2.96 | MA | Strong Sell |
| EMA 50 | 3.15 | MA | Strong Sell |
| SMA 50 | 3.24 | MA | Strong Sell |
| SMA 200 | 4.00 | MA | Strong Sell |
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
Stock news · updated daily
TORONTO, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announced that the United States District Court for the Southern District of New York has agreed to consolidate both the Company's direct action and a class action led by an individual investor alleging market manipulation. In addition, the court appointed experienced law firm Grant & Eisenhofer P.A. (“Grant & Eisenhofer”) as lead counsel in the class action. According to Grant & Eisenhofer, the firm has recovered over USD $30 Billion dollars for its clients to date in some of the most complex, often precedent-setting cases, in fights against the world's largest and richest opponents.
Thermo Fisher Scientific Inc. (NYSE: TMO - Get Free Report)'s stock price hit a new 52-week high on Tuesday. The company traded as high as $694.33 and last traded at $678.8880, with a volume of 218570 shares. The stock had previously closed at $676.76. Trending Headlines about Thermo Fisher Scientific Here are the key news stories
Strategic collaboration with leading global contract research organization to implement randomized, double-blind, placebo-controlled Phase 2 study of novel neuroprotective therapy Strategic collaboration with leading global contract research organization to implement randomized, double-blind, placebo-controlled Phase 2 study of novel neuroprotective therapy
AUSTIN, Texas, Sept. 30, 2026 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels.
TORONTO, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd.
TORONTO, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd.
Toronto, Ontario--(Newsfile Corp. - September 15, 2026) - Quantum BioPharma Ltd. (NASDAQ: QNTM) (FSE: 0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development, announces is pleased to announce its participation in the upcoming 3rd Annual ArcStone-Kingswood Growth Summit in Toronto, taking place on September 16, 2026, at the Sheraton Center Toronto Hotel.
AUSTIN, Texas, Sept. 14, 2026 (GLOBE NEWSWIRE) -- via IBN – NetworkNewsAudio announces the Audio Press Release (APR) titled “A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach,” featuring Quantum BioPharma Ltd . (NASDAQ: QNTM).
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 13, 2026 | -0.42 | -0.47 | Miss -11.9% | — |
| May 7, 2026 | -0.41 | -3.06 | Miss -643.4% | — |
| Mar 27, 2026 | -1.02 | -0.19 | Beat 81.2% | — |
| Nov 7, 2025 | -0.20 | -1.25 | Miss -525.0% | — |
| Aug 6, 2025 | -0.17 | -3.23 | Miss -1800.0% | — |
| May 14, 2025 | -0.37 | -1.41 | Miss -281.1% | $2.09M |
SEC EDGAR filings · last 12 months
Proxy statement (DEF 14A) disclosures
Annual filings (FY) with consensus forward estimates (hatched)
TTM vs. 5-year historical average (annual ratios)
| Metric | QNTM | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | -0.4x | -1.1x · sector 20.7x | Discount |
| Forward P/E (FY26E) | -1.2x | EPS est. -1.85 | Elevated |
| Price / Book | 1.9x | 1.6x | In line |
| Price / Sales | — | — | n/a |
| EV / EBITDA | -0.5x | -0.7x | Discount |
| Return on equity | -413.1% | — | Weak |
| Gross margin | 0.0% | 0.0% | n/a |
| Debt / Equity | 0.12 | 0.08 | Conservative |
| Piotroski / Altman Z | 2/9 | Z -25.29 | Distress |
Discounted cash flow model